InvestorsHub Logo
Followers 2
Posts 436
Boards Moderated 0
Alias Born 01/14/2014

Re: None

Sunday, 10/21/2018 4:49:55 AM

Sunday, October 21, 2018 4:49:55 AM

Post# of 247
There is clearly tumor lesion shrinkage, but falls short of a RECIST PR. Higher dose may get them there.

Based on experience with NY-ESO TCR therapy, the benefit of treatment may become evident at higher cell doses
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADAP News